UK Residual DNA Testing Market (2025-2030)
The UK Residual DNA Testing Market was valued at $15 Million in 2025 and projected to reach to $20.3 Million by 2030, representing a compound annual growth rate of 6.2%. The UK residual DNA testing market is positioned for steady growth as healthcare providers and pharmaceutical manufacturers prioritize contamination detection and quality assurance.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
UK Residual DNA Testing Market Trends and Insights
- The UK market reflects steady adoption of residual DNA testing across clinical diagnostics, pharmaceutical quality control, and forensic applications.
- UK healthcare providers and laboratories are increasingly integrating residual DNA testing into their workflows to ensure product safety, detect contamination, and support regulatory compliance with stringent UK and European standards. Driving growth in the UK market are heightened regulatory requirements, growing awareness of contamination risks in biopharmaceutical manufacturing, and expanding clinical applications in genetic testing and pathology.
- The UK's robust healthcare infrastructure and investment in precision medicine initiatives support market expansion through 2030.
- UK-based pharmaceutical and biotechnology companies are adopting advanced residual DNA detection technologies to meet both domestic and international quality assurance benchmarks, positioning the UK as a key market within the European residual DNA testing landscape..
Key Market Statistics
- CAGR (2025-2030) 6.2% CAGR
- Market Size, 2025 ~USD 15 Million
- Forecast, 2030 ~USD 20.3 Million
- Country UK
UK Residual DNA Testing Market Overview
Market Valuation :
The UK residual DNA testing market is valued at £15.0 million in 2025 and is projected to reach £20.3 million by 2030, demonstrating consistent growth in the healthcare diagnostics sector.
Growth Rate :
The UK market is expanding at a CAGR of 6.2% through 2030, reflecting steady adoption despite being slower than the global average of 16.4%, indicating a maturing but stable market.
Key Application Areas :
UK laboratories are increasingly adopting residual DNA testing across clinical diagnostics, pharmaceutical quality control, and forensic applications, driven by regulatory compliance and quality assurance requirements.
Healthcare Integration :
UK healthcare providers and diagnostic laboratories are progressively integrating residual DNA testing into standard protocols, supported by NHS initiatives and stringent quality standards in pharmaceutical manufacturing.
UK Residual DNA Testing Market Dynamics
- Regulatory frameworks such as ICH guidelines and UK MHRA standards are driving adoption across clinical laboratories and manufacturing facilities.
- The market benefits from increasing awareness of residual DNA risks in biopharmaceutical production and growing investment in advanced diagnostic capabilities. Looking ahead to 2030, the UK market will be shaped by technological advancements in testing methodologies, expansion of personalized medicine initiatives, and heightened focus on product safety.
- While growth remains moderate compared to global trends, the UK's robust healthcare infrastructure and stringent regulatory environment create a stable foundation for market expansion, particularly in pharmaceutical quality control and forensic applications..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Thermo Fisher Scientific Inc.
- Merck KGaA
- SANOFI
- Pfizer Inc.
- NOVARTIS
Key Takeaways
- The UK residual DNA testing market is valued at £15.0 million in 2025 and is forecast to reach £20.3 million by 2030, growing at a 6.2% CAGR.
- UK regulatory frameworks and biopharmaceutical manufacturing standards drive adoption of residual DNA testing across clinical and industrial laboratories.
- The UK market benefits from strong healthcare infrastructure, precision medicine investment, and stringent quality assurance requirements in pharmaceutical production.
- UK-based biotech and pharma companies are increasingly deploying residual DNA detection technologies to ensure compliance with domestic and European regulatory standards.
Residual DNA Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CELL & GENE THERAPY (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 16.4% from 2025 to 2030 |
| Largest Segment | POLYMERASE CHAIN REACTION (Technology) |
| Market Size Base Year (Billions) | ~USD 0.17 (2025) |
| Revenue Forecast (Billions) | ~USD 0.37 (2030) |
| Segments Covered | Offering, Type, Test Type, Technology, Application, End User |
UK Residual DNA Testing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Consumables
- Instruments & Software
By Test Type
- Bulk Lot Release Testing
- Final Product Release Testing
- Raw Material Testing
By Technology
- Dna Probe Hybridization
- Other Technologies
- Polymerase Chain Reaction
- Threshold Assays
By Application
- Cell & Gene Therapy
- Monoclonal Antibodies
- Other Applications
- Vaccines
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Pharmaceutical & Biopharmaceutical Companies
- Pharmaceutical & Biotechnology Companies
UK: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 1.7 | 1.79 | 1.89 | 1.99 | 2.11 | 2.24 | 2.39 | 2.56 | 6.3 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 4.35 | 4.63 | 4.94 | 5.29 | 5.67 | 6.09 | 6.57 | 7.11 | 7.5 |
| TOTAL | 6.05 | 6.42 | 6.83 | 7.28 | 7.78 | 8.34 | 8.96 | 9.66 | 7.2 |
UK: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER,2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 0.79 | 0.8 | 0.81 | 0.83 | 0.85 | 0.88 | 0.91 | 0.96 | 3.3 |
| CROS & CDMOS | 1.48 | 1.52 | 1.57 | 1.63 | 1.7 | 1.79 | 1.89 | 2.01 | 5.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 5.38 | 5.56 | 5.78 | 6.04 | 6.35 | 6.71 | 7.14 | 7.66 | 5.8 |
| TOTAL | 7.65 | 7.88 | 8.17 | 8.5 | 8.9 | 9.38 | 9.95 | 10.62 | 5.4 |
Target Audience
- Pharmaceutical Manufacturers : UK-based and international pharma companies need market data to optimize quality control investments, ensure MHRA compliance, and benchmark residual DNA testing adoption against competitors.
- Diagnostic Laboratory Operators : Clinical and forensic laboratories in the UK require insights into market growth, technology trends, and customer demand to justify capital expenditure and service expansion decisions.
- Healthcare System Planners : NHS trusts and healthcare commissioners need UK market intelligence to allocate resources effectively, plan diagnostic service capabilities, and support evidence-based healthcare delivery.
- Medical Device & Testing Solution Providers : Companies developing residual DNA testing technologies and equipment need UK-specific market data to guide product development, pricing strategies, and go-to-market approaches.
- Investment & Strategy Consultants : Private equity firms, management consultants, and business strategists require detailed UK market analysis to evaluate investment opportunities and support M&A due diligence in the diagnostics sector.
Key Companies in the UK Residual DNA Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Consumables (assay kits, reagents, plastics),Instruments (PCR, qPCR, automation),Software & informatics, |
| CHARLES RIVER LABORATORIES | United States | Public Company | Consumables (assay reagents, kits within services),Instruments & Software (PCR and data platforms used in labs),Services – Raw Material Testing, |
| MERCK KGAA | United States | Public Company | Consumables (reagents, kits, assay components),Instruments,Software & Services (including CDMO/CRO testing support), |
| MARAVAI LIFESCIENCES | United States | Public Company | Consumables,Instrument & Software,Services, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Consumables,Instrument & Software,PCR-based Testing Services, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Consumables,Instruments,Software & Informatics, |
| QIAGEN | Netherlands | Public Company | Consumables (sample prep, PCR, assays),Instruments (PCR, sample prep, QC),Software & Bioinformatics, |
| FUJIFILM CORPORATION | Japan | Public Company | Consumables (reagents, kits, media-linked components),Instruments & Software (PCR platforms, analytics, workflow tools),PCR-based Testing Services (CDMO-integrated), |
| SGS SOCIÉTÉ GéNéRALE DE SURVEILLANCE SA. | Switzerland | Public Company | Consumables-linked testing services,Instrument & software-enabled testing services,PCR-based residual DNA testing (all test types), |
| REVVITY | United States | Public Company | Consumables (reagents, assay kits, cartridges),Instruments,Software & Services, |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumables,Instruments & Software,PCR-based Testing Services, |
| SARTORIUS AG | United States | Public Company | Consumables (filters, reagents, lab plastics linked to residual DNA workflows),Instruments (bioreactors, filtration systems, analytical platforms used in DNA-controlled processes),Software & data analytics (lab data, PAT, and QC integration), |
| LONZA | Switzerland | Public Company | Consumables,Instruments & Software,PCR-based Testing Services, |
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a leading global provider of life sciences solutions, founded in 1956 and headquartered in the United States. With 125,000 employees, the company operates as a public corporation serving research, diagnostics, and bioproduction markets worldwide.
CHARLES RIVER LABORATORIES
Charles River Laboratories is a contract research organization founded in 1947, providing preclinical and clinical laboratory services to the pharmaceutical and biotechnology industries. The U.S.-based public company employs 19,000 people and supports drug development and safety testing globally.
MERCK KGAA
Merck KGaA is a diversified science and technology company founded in 1668, operating as a public company with 59,077 employees across the United States and globally. The company serves the pharmaceutical, life sciences, and performance materials sectors.
MARAVAI LIFESCIENCES
Maravai LifeSciences is a U.S.-based public company founded in 2014, specializing in critical reagents and services for the life sciences industry. With 416 employees, the company supports vaccine development, gene therapy, and molecular diagnostics.
EUROFINS SCIENTIFIC
Eurofins Scientific is a Luxembourg-based public company founded in 1987, operating a global network of laboratories with 65,694 employees. The company provides testing and analytical services across pharmaceutical, food, environmental, and consumer product sectors.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a U.S. public company founded in 1952, manufacturing and distributing life science research and clinical diagnostics products. With 7,450 employees, the company serves research institutions, hospitals, and laboratories worldwide.
QIAGEN
QIAGEN is a Netherlands-based public company founded in 1984, specializing in sample and assay technologies for molecular diagnostics and life sciences research. The company employs 5,500 people and serves clinical, pharmaceutical, and academic markets globally.
FUJIFILM CORPORATION
Fujifilm Corporation is a Japanese multinational public company founded in 1934, with 73,526 employees operating across imaging, information, and life sciences divisions. The company provides diagnostic imaging, pharmaceutical, and biotechnology solutions worldwide.
SGS SOCIÉTÉ GéNéRALE DE SURVEILLANCE SA.
SGS Société Générale de Surveillance SA. is a Switzerland-based public company founded in 1878, employing 83,000 people in inspection, verification, testing, and certification services. The company serves industries including pharmaceuticals, food, and consumer goods globally.
REVVITY
Revvity is a U.S.-based public company founded in 1937, providing analytical instruments, software, and services for research and diagnostics. With 11,000 employees, the company supports life sciences, diagnostics, and environmental testing applications.
INTERTEK GROUP PLC
Intertek Group PLC is a United Kingdom-based public company founded in 1885, employing 45,425 people in testing, inspection, and certification services. The company serves industries including pharmaceuticals, chemicals, and consumer products across the globe.
SARTORIUS AG
Sartorius AG is a U.S.-based public company founded in 1870, manufacturing laboratory and bioprocess equipment with 14,242 employees. The company provides filtration, weighing, and bioanalytical solutions for pharmaceutical and life sciences applications.
LONZA
Lonza is a Switzerland-based public company founded in 1897, employing 20,000 people in pharmaceutical and biotechnology manufacturing and services. The company specializes in custom development and manufacturing, cell therapy, and specialty ingredients.
Reasons to Buy this Report
- UK-Specific Market Sizing : Obtain precise valuation data for the UK market (£15.0M in 2025) with detailed forecasts through 2030, enabling accurate budget allocation and investment planning for UK-focused operations.
- Regulatory Compliance Insights : Understand how UK MHRA regulations and ICH guidelines are shaping residual DNA testing adoption, helping pharmaceutical and diagnostic companies align strategies with local compliance requirements.
- Competitive Landscape Analysis : Identify key players and market dynamics specific to the UK healthcare and pharmaceutical sectors, enabling informed competitive positioning and partnership opportunities.
- Growth Opportunity Assessment : Evaluate the 6.2% CAGR trajectory and identify high-potential segments within clinical diagnostics, quality control, and forensics to prioritize market entry or expansion strategies.
- Strategic Decision Support : Access actionable intelligence on UK healthcare provider adoption trends and laboratory integration patterns to support product development, marketing, and sales strategy refinement.
Frequently asked questions
What is the current size of the UK residual DNA testing market?
The UK residual DNA testing market is valued at £15.0 million in 2025 and is expected to grow to £20.3 million by 2030.
What is the growth rate of the UK residual DNA testing market?
The UK residual DNA testing market is projected to grow at a compound annual growth rate (CAGR) of 6.2% from 2025 to 2030.
What are the primary drivers of growth in the UK residual DNA testing market?
Key drivers include stringent UK and European regulatory requirements, increased biopharmaceutical manufacturing quality standards, expanding clinical diagnostic applications, and growing contamination risk awareness.
Which sectors in the UK are adopting residual DNA testing?
The UK market spans pharmaceutical manufacturing, biotechnology, clinical diagnostics, pathology laboratories, and forensic applications, with particular emphasis on biopharmaceutical quality control.
How does the UK market compare to the global residual DNA testing market?
The UK market grows at 6.2% CAGR, which is more moderate than the global market's 16.4% CAGR, reflecting the UK's mature healthcare infrastructure and established regulatory environment.
RESEARCH METHODOLOGY
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global residual DNA testing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), Health Canada, European Medicines Agency (EMA), and Centers for Disease Control and Prevention (CDC). These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the residual DNA testing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Residual DNA testing involves the detection and quantification of DNA impurities from host cells present in biopharmaceutical products. This testing is a critical component in the quality assurance of biologics, as it assesses the levels of residual DNA that may remain in the final product, bulk intermediates, or raw materials post-purification. The market for residual DNA testing encompasses a diverse array of analytical tools and services tailored to meet stringent regulatory requirements. Compliance with guidelines established by the FDA, WHO, and GxP standards necessitates a thorough evaluation of host cell DNA to mitigate risks and ensure safety and efficacy in biologics. This regulatory landscape makes residual DNA testing a vital focus area in the development and manufacturing of biologic products, emphasizing the need for precision and reliability in these assessments.
Stakeholders
- Pharmaceutical & biotechnology companies
- Academic researchers and government research organizations
- Private research institutes
- Custom residual DNA testing service providers
- Contract development & manufacturing organizations (CDMOs)
- Life Science Companies
- Contract research organizations (CROs)
- Market research & consulting firms
- Venture capitalists
Report Objectives
- To define, describe, and forecast the global residual DNA testing market by offering, technology, test type, application, end user (product), end user (service), and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall residual DNA testing market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- Track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the residual DNA testing market.
- To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the residual DNA testing market.
Get the Full Residual DNA Testing Market Report
Full forecast, segment splits, and company analysis for all Residual DNA Testing Market.
- Rest Of Europe Residual DNA Testing Market
- Rest Of Asia Pacific Residual DNA Testing Market
- Rest Of Latin America Residual DNA Testing Market
- Rest Of GCC Countries Residual DNA Testing Market
- Saudi Arabia Residual DNA Testing Market
- GCC Countries Residual DNA Testing Market
- Rest Of Middle East Residual DNA Testing Market
- Canada Residual DNA Testing Market
- US Residual DNA Testing Market
- Germany Residual DNA Testing Market
- France Residual DNA Testing Market
- Italy Residual DNA Testing Market
- Spain Residual DNA Testing Market
- China Residual DNA Testing Market
- Japan Residual DNA Testing Market
- India Residual DNA Testing Market
- South Korea Residual DNA Testing Market
- Australia Residual DNA Testing Market
- Brazil Residual DNA Testing Market
- Mexico Residual DNA Testing Market
- UAE Residual DNA Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
